

Walter Maetzler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5241387/walter-maetzler-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291
papers

11,506
citations

52
h-index

97
g-index

324
ext. papers

14,481
ext. citations

5.5
avg. IF

6
L-index

#	Paper	IF	Citations
291	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014 , 46, 989-93	36.3	1261
290	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011 , 43, 699-705	36.3	386
289	The release and trans-synaptic transmission of Tau via exosomes. <i>Molecular Neurodegeneration</i> , 2017 , 12, 5	19	324
288	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-82		305
287	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
286	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
285	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016 , 98, 500-513	11	225
284	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1628-37	7	216
283	A pan-European study of the C9orf72 repeat associated with FTL: geographic prevalence, genomic instability, and intermediate repeats. <i>Human Mutation</i> , 2013 , 34, 363-73	4.7	208
282	Progression of Parkinson's disease in the clinical phase: potential markers. <i>Lancet Neurology</i> , 2009 , 8, 1158-71	24.1	208
281	BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. <i>Journal of Psychiatric Research</i> , 2007 , 41, 387-94	5.2	204
280	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014 , 29, 470-8	7	201
279	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , 2016 , 91, 56-66	13.9	178
278	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. <i>Molecular Psychiatry</i> , 2015 , 20, 647-656	15.1	167
277	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. <i>Neurobiology of Disease</i> , 2009 , 34, 107-12	7.5	158
276	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014 , 23, 6139-46	5.6	152
275	GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , 2015 , 30, 407-11	7	135

274	Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. <i>Archives of Neurology</i> , 2011 , 68, 932-7		131
273	Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. <i>PLoS ONE</i> , 2013 , 8, e73094	3.7	124
272	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016 , 13, 24	5.3	120
271	[11C]PIB binding in Parkinson's disease dementia. <i>NeuroImage</i> , 2008 , 39, 1027-33	7.9	120
270	S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF- α pathway. <i>Brain</i> , 2012 , 135, 3336-47	11.2	118
269	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019 , 34, 657-663	7	115
268	Comparison of acceleration signals of simulated and real-world backward falls. <i>Medical Engineering and Physics</i> , 2011 , 33, 368-73	2.4	111
267	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , 2013 , 12, 514-24	24.1	108
266	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. <i>Movement Disorders</i> , 2014 , 29, 479-87	7	106
265	A clinical view on the development of technology-based tools in managing Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1263-71	7	96
264	Health-Related Quality of Life in patients with Parkinson's disease--A systematic review based on the ICF model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 61, 26-34	9	95
263	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. <i>Movement Disorders</i> , 2016 , 31, 1283-92	7	92
262	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2013 , 20, 102-8	6	91
261	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , 2007 , 25, 473-82	7.5	91
260	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15	1.2	87
259	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014 , 128, 397-410	14.3	83
258	Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. <i>Acta Diabetologica</i> , 2014 , 51, 679-81	3.9	79
257	Prodromal features for Parkinson's disease--baseline data from the TREND study. <i>European Journal of Neurology</i> , 2014 , 21, 766-72	6	76

256	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology, The</i> , 2020 , 19, 462-470	24.1	74
255	Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. <i>Neurobiology of Aging</i> , 2012 , 33, 2949.e13-7	5.6	69
254	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017 , 38, 297-309	4.7	66
253	Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. <i>Neurobiology of Aging</i> , 2013 , 34, 439-50	5.6	63
252	Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. <i>Journal of Alzheimer's Disease</i> , 2009 , 18, 331-7	4.3	60
251	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , 2018 , 9, 17455-17465	3.3	59
250	Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. <i>PLoS ONE</i> , 2011 , 6, e27831	3.7	58
249	Impaired trunk stability in individuals at high risk for Parkinson's disease. <i>PLoS ONE</i> , 2012 , 7, e32240	3.7	58
248	Gait analysis with wearables predicts conversion to parkinson disease. <i>Annals of Neurology</i> , 2019 , 86, 357-367	9.4	57
247	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , 2011 , 26, 2335-42	7	55
246	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012 , 119, 39-52	4.3	54
245	Motor signs in the prodromal phase of Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 627-33	7	54
244	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017 , 32, 1025-1034	7	53
243	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 1401-1408	7	53
242	Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016 , 26, 73-7	3.6	53
241	Quantitative home-based assessment of Parkinson's symptoms: the SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , 2015 , 15, 89	3.1	52
240	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , 2016 , 91, 59-68	7.5	52
239	Highly potent soluble amyloid- β seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014 , 137, 2909-2915	11.2	52

238	The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?. <i>PLoS ONE</i> , 2015 , 10, e0126804	3.7	50
237	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016 , 38, 214.e7-214.e10	5.6	49
236	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1270-1272	5.5	49
235	Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 171-9	4.3	48
234	Intra-Rater, Inter-Rater and Test-Retest Reliability of an Instrumented Timed Up and Go (iTUG) Test in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2016 , 11, e0151881	3.7	47
233	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. <i>Genetics in Medicine</i> , 2018 , 20, 240-249	8.1	44
232	Validating Alzheimer's disease micro RNAs using next-generation sequencing. <i>Alzheimer's and Dementia</i> , 2016 , 12, 565-76	1.2	44
231	The FARSEEING real-world fall repository: a large-scale collaborative database to collect and share sensor signals from real-world falls. <i>European Review of Aging and Physical Activity</i> , 2016 , 13, 8	6.5	43
230	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017 , 8, 457	4.1	43
229	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. <i>JAMA Oncology</i> , 2020 , 6, 714-723	13.4	42
228	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 51	5.3	42
227	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018 , 46 Suppl 1, S53-S56	3.6	41
226	A combined miRNA-piRNA signature to detect Alzheimer's disease. <i>Translational Psychiatry</i> , 2019 , 9, 250	8.6	41
225	Proposal for a multiphase fall model based on real-world fall recordings with body-fixed sensors. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2012 , 45, 707-15	2.7	41
224	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. <i>Movement Disorders</i> , 2009 , 24, 1504-11	7	40
223	Are Hypometric Anticipatory Postural Adjustments Contributing to Freezing of Gait in Parkinson's Disease?. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 36	5.3	38
222	Technical and clinical view on ambulatory assessment in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 139-47	3.8	38
221	Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs. <i>Genomics, Proteomics and Bioinformatics</i> , 2019 , 17, 430-440	6.5	38

220	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015 , 122, 419-25	4.3	37
219	Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid- β pathway. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 119-26	4.3	37
218	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010 , 25, 1464-9	7	37
217	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , 2016 , 31, 593-6	7	37
216	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , 2011 , 26, 176-81	7	36
215	Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. <i>Neurobiology of Aging</i> , 2011 , 32, 1599-606	5.6	35
214	Emerging therapies for gait disability and balance impairment: promises and pitfalls. <i>Movement Disorders</i> , 2013 , 28, 1576-86	7	34
213	Alterations in Blood Monocyte Functions in Parkinson's Disease. <i>Movement Disorders</i> , 2019 , 34, 1711-1721		33
212	Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. <i>Archives of Neurology</i> , 2011 , 68, 925-31		33
211	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , 2016 , 13, 122	10.1	33
210	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 31-61	5.3	33
209	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , 2020 , 88, 320-331	9.4	32
208	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015 , 6, 216	4.1	31
207	Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2010 , 43, 224-8	2.7	31
206	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. <i>European Journal of Neurology</i> , 2017 , 24, 427-e6	6	30
205	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 279-87	5.3	30
204	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. <i>Frontiers in Human Neuroscience</i> , 2018 , 12, 226	3.3	29
203	Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. <i>Acta Neurologica Scandinavica</i> , 2013 , 127, 362-70	3.8	29

202	Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. <i>Parkinson's Disease</i> , 2011 , 2011, 540843	2.6	29
201	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28
200	Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. <i>PLoS ONE</i> , 2014 , 9, e88604	3.7	28
199	SNCA: major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1217-21		28
198	Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. <i>Current Alzheimer Research</i> , 2010 , 7, 409-14	3	27
197	Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis. <i>Frontiers in Neurology</i> , 2018 , 9, 668	4.1	27
196	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Movement Disorders</i> , 2012 , 27, 151-5	7	26
195	Risk for femoral fractures in Parkinson's disease patients with and without severe functional impairment. <i>PLoS ONE</i> , 2014 , 9, e97073	3.7	26
194	In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Journal of Neural Transmission</i> , 2011 , 118, 1191-7	4.3	26
193	The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 937-42	4.3	26
192	Ectopic parvalbumin expression in mouse forebrain neurons increases excitotoxic injury provoked by ibotenic acid injection into the striatum. <i>Experimental Neurology</i> , 2004 , 186, 78-88	5.7	26
191	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 32-7	5.5	25
190	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015 , 36, 1072-4	5.6	25
189	Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. <i>International Journal of Alzheimer's Disease</i> , 2012 , 2012, 391438	3.7	25
188	Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , 2016 , 26, 41-6	3.6	24
187	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , 2016 , 37, 208.e11-208.e17	5.6	24
186	Associations between Early Markers of Parkinson's Disease and Sarcopenia. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 53	5.3	24
185	No association of GBA mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013 , 20, e61-2	6	24

184	Decreased β synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 31, 413-6	2.6	24
183	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. <i>PLoS ONE</i> , 2016 , 11, e0151997	3.7	24
182	Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 22	5.3	23
181	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 1245-1248	7	23
180	Effect of Fear of Falling on Turning Performance in Parkinson's Disease in the Lab and at Home. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 78	5.3	23
179	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 764-7	5.5	23
178	Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. <i>Movement Disorders</i> , 2010 , 25, 1040-6	7	23
177	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 147	5.3	23
176	Wearables for gait and balance assessment in the neurological ward - study design and first results of a prospective cross-sectional feasibility study with 384 inpatients. <i>BMC Neurology</i> , 2018 , 18, 114	3.1	23
175	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016 , 31, 742-7	7	22
174	What is Functional Mobility Applied to Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 121-130	5.3	22
173	Nepriylisin activity in cerebrospinal fluid is associated with dementia and amyloid- β 2 levels in Lewy body disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 933-8	4.3	22
172	Altered serum IgG levels to β synuclein in dementia with Lewy bodies and Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e64649	3.7	22
171	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. <i>PLoS ONE</i> , 2016 , 11, e0149349	3.7	22
170	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. <i>Current Alzheimer Research</i> , 2016 , 13, 654-62	3	22
169	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. <i>Movement Disorders</i> , 2020 , 35, 495-499	7	22
168	The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 48, 74-81	3.6	21
167	Mild parkinsonian signs in the elderly--is there an association with PD? Cross-sectional findings in 992 individuals. <i>PLoS ONE</i> , 2014 , 9, e92878	3.7	21

166	How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review. <i>Npj Parkinson's Disease</i> , 2021 , 7, 25	9.7	21
165	Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. <i>PLoS ONE</i> , 2016 , 11, e0150552	3.7	21
164	Less Is More - Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 435	5.3	20
163	Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 465-74	1.2	20
162	Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson's Disease in the Home or a Home-like Environment. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 429-454	5.3	20
161	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017 , 8, 135	4.1	20
160	Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. <i>Neuroepidemiology</i> , 2013 , 41, 174-82	5.4	20
159	GABA(B) receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. <i>Neuroscience Letters</i> , 2006 , 395, 118-23	3.3	20
158	Development of a standard fall data format for signals from body-worn sensors : the FARSEEING consensus. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2013 , 46, 720-6	2.7	19
157	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , 2019 , 34, 1069-1073	7	18
156	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. <i>Neurodegenerative Diseases</i> , 2017 , 17, 83-88	2.3	18
155	Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. <i>PLoS ONE</i> , 2012 , 7, e48042	3.7	18
154	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. <i>PLoS ONE</i> , 2018 , 13, e0206536	3.7	18
153	Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. <i>Frontiers in Neurology</i> , 2018 , 9, 652	4.1	18
152	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017 , 32, 1780-1783	7	17
151	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 165, 88-93	2	17
150	Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. <i>PLoS ONE</i> , 2015 , 10, e0123914	3.7	17
149	Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 367-75	4.3	17

148	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. <i>PLoS ONE</i> , 2015 , 10, e0138863	3.7	17
147	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 4	5.3	17
146	How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, S41-S45	5.3	17
145	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 423-432	5.3	16
144	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 413-6	3.6	16
143	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1427-34	3.6	16
142	Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 154	5.3	16
141	Participatory design in Parkinson's research with focus on the symptomatic domains to be measured. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 187-96	5.3	16
140	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , 2015 , 45, 282-97	5.4	16
139	Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. <i>PLoS ONE</i> , 2014 , 9, e114566	3.7	16
138	Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. <i>American Journal of Pathology</i> , 2010 , 177, 829-39	5.8	16
137	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , 2019 , 3, 116-132	7.1	16
136	Common diseases alter the physiological age-related blood microRNA profile. <i>Nature Communications</i> , 2020 , 11, 5958	17.4	16
135	Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 288-92	7	15
134	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014 , 10, 530-540.e1	1.2	15
133	Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 126-30	3.6	14
132	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. <i>Frontiers in Neurology</i> , 2018 , 9, 500	4.1	14
131	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. <i>Neurobiology of Disease</i> , 2009 , 35, 296-301	7.5	14

130	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. <i>Movement Disorders</i> , 2016 , 31, 1337-8	7	14
129	Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study. <i>Cerebellum</i> , 2019 , 18, 340-348	4.3	14
128	A neurodegenerative vascular burden index and the impact on cognition. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 161	5.3	13
127	Increased [¹¹ C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1060-2	5.5	13
126	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. <i>Journal of Neural Transmission</i> , 2009 , 116, 599-605	4.3	13
125	Microcalcification after excitotoxicity is enhanced in transgenic mice expressing parvalbumin in all neurones, may commence in neuronal mitochondria and undergoes structural modifications over time. <i>Neuropathology and Applied Neurobiology</i> , 2009 , 35, 165-77	5.2	13
124	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	13
123	Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity. <i>Npj Parkinson's Disease</i> , 2021 , 7, 24	9.7	12
122	Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 235	5.3	12
121	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, ESynuclein in PD. <i>Movement Disorders</i> , 2021 , 36, 1216-1228	7	12
120	Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. <i>Frontiers in Human Neuroscience</i> , 2019 , 13, 59	3.3	11
119	The detection of age groups by dynamic gait outcomes using machine learning approaches. <i>Scientific Reports</i> , 2020 , 10, 4426	4.9	11
118	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. <i>Journal of Neuroimmunology</i> , 2016 , 290, 60-5	3.5	11
117	Arm swing asymmetry in overground walking. <i>Scientific Reports</i> , 2018 , 8, 12803	4.9	11
116	Is the Assessment of 5 Meters of Gait with a Single Body-Fixed-Sensor Enough to Recognize Idiopathic Parkinson's Disease-Associated Gait?. <i>Annals of Biomedical Engineering</i> , 2017 , 45, 1266-1278	4.7	11
115	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 281-90	5.3	11
114	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , 2015 , 15, 192	3.1	11
113	Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 286	5.3	11

112	Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes. <i>Sensors</i> , 2020 , 20,	3.8	11
111	Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 963-976	7	11
110	Validation of IMU-based gait event detection during curved walking and turning in older adults and Parkinson's Disease patients. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021 , 18, 28	5.3	11
109	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 1123	4.1	11
108	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 1233-1238	7	10
107	Association of Plasma A β 0 Peptides, But Not A β 2, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 161-9	4.3	10
106	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 42	9	10
105	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2387-2395	8.8	10
104	SNPs in A β clearance proteins: Lower CSF A β levels and earlier onset of dementia in PD. <i>Neurology</i> , 2017 , 89, 2335-2340	6.5	10
103	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017 , 49, 214.e13-214.e15	5.6	10
102	Using multi-dimensional dynamic time warping for TUG test instrumentation with inertial sensors 2012 ,		10
101	Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 351-67	2.6	10
100	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 121	5.3	10
99	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , 2021 , 36, 76-82	7	10
98	Postural transitions detection and characterization in healthy and patient populations using a single waist sensor. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020 , 17, 70	5.3	9
97	No relevant association of kinematic gait parameters with Health-related Quality of Life in Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0176816	3.7	9
96	Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 646	4.1	9
95	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. <i>Neurodegenerative Diseases</i> , 2016 , 16, 317-23	2.3	9

94	Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia. <i>PLoS ONE</i> , 2013 , 8, e82902	3.7	9
93	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020 , 17, 1736-1746	6.4	9
92	Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. <i>Journal of Neuropsychology</i> , 2020 , 14, 69-84	2.6	9
91	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). <i>Neurobiology of Aging</i> , 2018 , 70, 242-246	5.6	9
90	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. <i>Ultraschall in Der Medizin</i> , 2017 , 38, 294-300	3.8	8
89	Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 75	5.3	8
88	Technical validation of real-world monitoring of gait: a multicentric observational study. <i>BMJ Open</i> , 2021 , 11, e050785	3	8
87	The Use of Virtual and Immersive Technology in Creating Personalized Multisensory Spaces for People Living With Dementia (SENSE-GARDEN): Protocol for a Multisite Before-After Trial. <i>JMIR Research Protocols</i> , 2019 , 8, e14096	2	8
86	Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. <i>BMJ Open</i> , 2020 , 10, e038704	3	8
85	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , 2021 , 96, e399-e411	6.5	8
84	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. <i>Journal of Neural Transmission</i> , 2015 , 122, 1167-74	4.3	7
83	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study. <i>BMC Geriatrics</i> , 2020 , 20, 45	4.1	7
82	Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. <i>Gerontology</i> , 2020 , 66, 409-415	5.5	7
81	Parkinson disease in 2017: Changing views after 200 years of Parkinson disease. <i>Nature Reviews Neurology</i> , 2018 , 14, 70-72	15	7
80	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1349-1353	7	7
79	Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study. <i>Movement Disorders</i> , 2017 , 32, 1254-1256	7	7
78	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 213	5.3	7
77	Lowered serum amyloid- β 42 autoantibodies in individuals with lifetime depression. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 95-100	4.3	7

76	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , 2021 , 90, E1-E12	9.4	7
75	Freezing of Swallowing. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 490-493	2.2	7
74	Parkinson's disease: evolution of cognitive impairment and CSF Aβ profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 165-170	5.5	7
73	Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2018 , 9, 1084	4.1	7
72	Functional movement disorders in neurogeriatric inpatients : Underdiagnosed, often comorbid to neurodegenerative disorders and treatable. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019 , 52, 324-329 ^{2.7}		6
71	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 Synuclein antibody. <i>Acta Neuropathologica</i> , 2014 , 128, 893-5	14.3	6
70	Comment: why do nondopaminergic features in Parkinson disease matter?. <i>Neurology</i> , 2014 , 82, 417	6.5	6
69	Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. <i>Npj Digital Medicine</i> , 2021 , 4, 149	15.7	6
68	Short-term physical exercise impacts on the human holobiont obtained by a randomised intervention study. <i>BMC Microbiology</i> , 2021 , 21, 162	4.5	6
67	Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes. <i>Neurodegenerative Diseases</i> , 2017 , 17, 135-144	2.3	5
66	Classification of Neurological Patients to Identify Fallers Based on Spatial-Temporal Gait Characteristics Measured by a Wearable Device. <i>Sensors</i> , 2020 , 20,	3.8	5
65	Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 8-14 ^{3.6}		5
64	Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 271	5.3	5
63	Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease. <i>Journal of Neurology</i> , 2021 , 268, 2506-2514	5.5	5
62	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2019 , 10, 372	4.1	4
61	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , 2019 , 10, 523-530	2.5	4
60	Quantitative motor assessment of dyskinesias in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015 , 122, 1271-8	4.3	4
59	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 455-462	5.3	4

58	Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson's disease. <i>BMJ Open</i> , 2020 , 10, e041303	3	4
57	Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients. <i>Neuropsychology</i> , 2020 , 34, 447-455	3.8	4
56	Wearable Health Technology to Quantify the Functional Impact of Peripheral Neuropathy on Mobility in Parkinson's Disease: A Systematic Review. <i>Sensors</i> , 2020 , 20,	3.8	4
55	Gait Analysis with Wearables Can Accurately Classify Fallers from Non-Fallers: A Step toward Better Management of Neurological Disorders. <i>Sensors</i> , 2020 , 20,	3.8	4
54	Quantification of Arm Swing during Walking in Healthy Adults and Parkinson's Disease Patients: Wearable Sensor-Based Algorithm Development and Validation. <i>Sensors</i> , 2020 , 20,	3.8	4
53	Reliability of IMU-Derived Static Balance Parameters in Neurological Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	4
52	Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity. <i>NeuroReport</i> , 2017 , 28, 1061-1065	1.7	3
51	Longitudinal changes of nerve conduction velocity, distal motor latency, compound motor action potential duration, and skin temperature during prolonged exposure to cold in a climate chamber. <i>International Journal of Neuroscience</i> , 2012 , 122, 528-31	2	3
50	βSynuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2508-2518	7	3
49	Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 197-209	4.3	3
48	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. <i>Cerebellum</i> , 2021 , 20, 662-666	4.3	3
47	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. <i>Journal of Neurology</i> , 2018 , 265, 1976-1984	5.5	3
46	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 55	5.3	2
45	Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia. <i>Frontiers in Neurology</i> , 2014 , 5, 236	4.1	2
44	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , 2021 , 28, 1557-1565	6	2
43	Private variants in PRKN are associated with late-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 75, 24-26	3.6	2
42	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , 2021 , 96, e904-e915	6.5	2
41	Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs. <i>Movement Disorders</i> , 2019 , 34, 144-146	7	2

40	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 208-214	2.2	2
39	Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. <i>Sensors</i> , 2021 , 21,	3.8	2
38	Reliability of IMU-Derived Temporal Gait Parameters in Neurological Diseases.. <i>Sensors</i> , 2022 , 22,	3.8	2
37	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinson's Disease</i> , 2017 , 2017, 8582740	2.6	1
36	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 260	5.3	1
35	Wie sollen wir Patienten mit Demenz behandeln? Die ethisch problematische Funktion der Antidementiva. <i>Ethik in Der Medizin</i> , 2007 , 19, 270-280	0.5	1
34	Cerebellar rTMS in PSP: a double blind sham-controlled study using mobile health technology		1
33	Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson's Disease.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 722830	5.3	1
32	Increased functional connectivity in a population at risk of developing Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021 , 92, 1-6	3.6	1
31	Sarkopenie 2019 , 69-84		1
30	Neurogeriatrics-a vision for improved care and research for geriatric patients with predominating neurological disabilities. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2020 , 53, 340-346	2.7	1
29	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1122-1131	5.3	1
28	Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease. <i>Sensors</i> , 2021 , 21,	3.8	1
27	A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021 , 7, 49	9.7	1
26	Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 37-43	3.6	1
25	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 783996	5.3	1
24	Therapeutic climbing in Parkinson's disease: Differences in self-reported health and well-being, feasibility and clinical changes.. <i>Physiotherapy Theory and Practice</i> , 2022 , 1-15	1.5	0
23	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , 2021 , 12, 757748	4.1	0

22	Digital assessment at home - mPower against Parkinson disease. <i>Nature Reviews Neurology</i> , 2021 , 17, 661-662	15	o
21	Arm swing responsiveness to dopaminergic medication in Parkinson's disease depends on task complexity. <i>Npj Parkinson's Disease</i> , 2021 , 7, 89	9.7	o
20	Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 250	5.3	o
19	Age-related deterioration of performance and increase of cortex activity comparing time- versus item-controlled fNIRS measurement. <i>Scientific Reports</i> , 2021 , 11, 6766	4.9	o
18	The Power of Musification: Sensor-Based Music Feedback Improves Arm Swing in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1240-1247	2.2	o
17	Functional Movement Disorder in Older Adults. <i>Current Clinical Neurology</i> , 2022 , 197-203	0.1	o
16	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology.. <i>Journal of the Neurological Sciences</i> , 2022 , 435, 120197	3.2	o
15	Reply to "Quantitative Motor Functioning in Prodromal Parkinson Disease". <i>Annals of Neurology</i> , 2019 , 86, 981-982	9.4	
14	Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observation. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 83-84	3.6	
13	Bedeutung der Mobilitätsmessung durch Zukunftsmusik oder sinnvoll?. <i>Geriatric-Report</i> , 2018 , 13, 34-36	o	
12	Mit regelmäßigem Training wieder besser unterwegs. <i>Geriatric-Report</i> , 2019 , 14, 24-27	o	
11	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. <i>Frontiers in Neurology</i> , 2019 , 10, 833	4.1	
10	Progressive Supranuclear Palsy and Dementia 2015 , 147-157		
9	Reply: Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , 2012 , 27, 1584-1585	7	
8	Biomarkers in Alzheimer's disease and lewy body disorders with dementia. <i>International Journal of Alzheimer's Disease</i> , 2013 , 2013, 473181	3.7	
7	Biomarkers of Alzheimer's and Parkinson's Disease 2010 , 89-117		
6	Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF) 2019 , 7-22		
5	Osteoporose beim Idiopathischem Parkinson-Syndrom: Risikopatienten erkennen, diagnostizieren und richtig behandeln. <i>Osteologie</i> , 2019 , 28, 268-273	0.2	

- 4 Parkinson-Therapie beim alten Patienten. *Neurotransmitter*, **2017**, 28, 40-47 0.1
- 3 Gangstörungen bei Senioren: So klären Sie neurologische Ursachen ab. *Geriatric-Report*, **2018**, 13, 28-30 0
- 2 Postural Sway in Parkinson's Disease and Multiple Sclerosis Patients During Tasks With Different Complexity.. *Frontiers in Neurology*, **2022**, 13, 857406 4.1
- 1 Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease.. *Journal of Neural Transmission*, **2022**, 1 4.3